Ser615
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser615  -  eNOS (human)

Site Information
SYKIRFNsISCSDPL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448656

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 ) , mutation of modification site ( 3 ) , phospho-antibody ( 2 , 3 , 4 ) , phosphopeptide mapping ( 3 ) , western blotting ( 3 , 4 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
BAE ( 3 ) , breast ( 1 ) , COS (fibroblast) ( 2 ) , HAEC (endothelial) ( 4 )

Upstream Regulation
Regulatory protein:
PTEN (human) ( 4 )
Kinases, in vitro:
Akt1 (human) ( 3 ) , PKACA (human) ( 3 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Fulton D, et al. (2004) Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release. J Biol Chem 279, 30349-57
15136572   Curated Info

3

Michell BJ, et al. (2002) Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J Biol Chem 277, 42344-51
12171920   Curated Info

4

Church JE, et al. Inhibition of endothelial nitric oxide synthase by the lipid phosphatase PTEN. Vascul Pharmacol 52, 191-8
19962452   Curated Info